Introduction
T he World Health Organization (WHO) has compared hepatitis C to a "viral time bomb" and estimates that about 180 million people (some 3% of the world's population) are infected with hepatitis C virus (HCV), 130 million of whom are chronic carriers at risk of developing liver cirrhosis and/or liver cancer. Three to four million persons are newly infected each year, 70% of whom will develop chronic hepatitis. HCV is responsible for 50-76% of all liver cancer cases, and two thirds of all liver transplants in the developed world (1) . World Health Statistics 2008 lists cirrhosis of the liver as the 18 th commonest cause of mortality in the world, and it is estimated that by 2030, liver cancer will become the 13 th commonest cause (2) . The prevalence of hepatitis varies from country to country, and at times it will also vary among different regions of the same country. The epidemiological estimates by WHO show that the prevalence of hepatitis C is low (< 1%) in Australia, Canada and northern Europe, and about 1% in countries of medium endemicity, such as the USA and most of Europe. It is high (>2%) in many countries of Africa, Latin America, Central and South-East Asia. In these countries, prevalence figures between 5% and 10% are frequently reported (1) .
Collecting and comparing health data from across a country is a way to describe health problems, identify trends and help decision-makers set priorities. The global epidemiology of hepatitis C is well established. However, its epidemiology in Pakistan is ill-defined.
Hepatitis C in Pakistan
Most of the data have come from hospital-based studies, because there is a dearth of communitybased ones (3) (4) (5) . Although the National Survey of Hepatitis has concluded, its results have not yet been officially published, except for a few presentations made by researchers at official meetings. This review summarizes the available data on the epidemiology of hepatitis C since the first report of its recognition in 1992.
HCV-Related Pakistani Data
All available Pakistani data published or unpublished till the writing of this article were collected by a literature search through electronic databases like Pubmed, Pakmedinet, Yahoo and Google etc. Unpublished data from any source, if accessible, were also reviewed. Data from 132 published studies and 3 unpublished data sets were gathered and grouped in six categories, based on the type of population studied i.e. 1) general population, 2) blood donors, 3) patients with liver diseases, 4) patients with diseases other than hepatic diseases, 5) pregnant women and 6) children. Most of the data (78.5%) pertained to the years [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] . Year by year distribution of this data is given in Table 1 .
General Population
Twenty-five studies pertained to the serofrequency of hepatitis C in the general population. Details are given in Table 2 . The majority of these studies (92%) were conducted during the period 2000-2008. Two studies were conducted in the nineties (6, 7) . The data of 178,322 persons were included in this group. Unfortunately, there was no study from any major city of Balochistan, or from the NWFP provinces. The frequency of HCV infection ranged from 0.4% in Karachi (6) to 33.7% in Jarwar (Sindh) (28) . The mean frequency was 4.7% (95% confidence interval [CI]: 4.6 -4.8).
Blood Donors
Blood donor data constituted the largest data set. There were 27 studies and 3 unpublished data sets in this group. The total population covered in this group was 982,481 over the period [1996] [1997] [1998] [1999] [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] (Table  3) . The studies covered all provinces of Pakistan. The serofrequency of HCV ranged from 0.3% in Multan (31) to 12.5% in Islamabad (32) . The mean frequency was 3.0% (95% CI: 3.0-3.1). Only five studies (29, (32) (33) (34) (35) showed a frequency of > 5%.
Patients with Liver Diseases
Forty-one studies dealing with the frequency of hepatitis C among patients with liver diseases were found, covering 7,765 patients over a period of 27 years from 1992 to 2008 (Table 4 , and 5). Liver diseases included cirrhosis, chronic liver disease, chronic active hepatitis and hepatocellular carcinoma.
Fourteen studies (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) pertained to cirrhosis patients. The number of individuals included in these studies was 1,902. HCV serofrequency in these individuals ranged from 10.5-79.6%, with an overall prevalence of 44.9% (95% CI = 42.6 -47.2). Eleven studies (39, (51) (52) (53) (54) (55) (56) (57) (58) (59) 69) covering 3,144 patients with chronic liver disease showed a range of 13.3% to 86.0% HCV serofrequency. The mean frequency was 52.9% (95% CI: 51.1-54.7). In 10 studies (36, 39, 40, 42, (60) (61) (62) (63) (64) (65) The HCV serofrequency in 739 cases of hepatocellular carcinoma was investigated (Table 5) , and it ranged from 24% to 67.9%. The mean frequency in this subgroup was 50.6% (95% CI : 46.9-54.3). One thousand nine hundred and eighty patients with acute/chronic hepatitis from 6 studies had 58.2% (95% CI : 55.7-60.4) HCV serofrequency (46, 51, 57, (66) (67) (68) .
Patients with Diseases Other than Hepatic Diseases
Sixteen studies focused on HCV serofrequency in patients with various diseases other than liver diseases (Table 6) (10, (70) (71) (72) (73) (74) (75) (76) (77) (78) (79) (80) (81) (82) (83) (84) (85) . These studies spanned a period of 8 years, from 1999 to 2006, and covered major cities. The mean frequency of HCV infection in patients with various medical diseases was 20.4% (95% CI : 18.4-22.5), 38% in haematological diseases (95% CI : 33.6-42.5), 7.9% among surgical diseases (95% CI : 6.9 -9.0), and 1.3% in dental diseases.
Pregnant Women
Eleven studies (86) (87) (88) (89) (90) (91) (92) (93) (94) (95) (96) dealing with the serofrequency of HCV among pregnant women were found (Table 7) . These studies spanned a period of 13 years from 1996 to 2008 and covered 6,148 women. The frequency in this group ranged from 3.3% to 29.1%. Overall serofrequency in this group was 7.3% (95% CI = 6.7 -8.0).
Children
Data from four studies (18, 86, 97, 98) covering 4,472 healthy children were analyzed (Table 8) . HCV serofrequency among children ranged from 0.4% to 36.25%. The mean frequency was 1.8% (95% CI = 4.6 -7.5). One study from Lahore in 1996 reported a 4.1% perinatal transmission of HCV in children of HCV-positive mothers. The serofrequency of HCV in thalassemics, and hemophiliacs was 35-42% (75) (76) (77) (78) and 25% (79) , respectively.
Discussion
Many researchers have tried to derive a national or regional figure for HCV serofrequency based on the available data (99) (100) (101) . In 2005, Umar M and Khaar HTB (99) , from Rawalpindi, collected data from various studies and reported a 9.8% frequency in 79,192 individuals. In 2006, Hafeez (99) , from Islamabad, collected data from 98 studies and produced an estimate of 5.3%. Raja and Janjua (101) , from Essex (UK), analyzed studies available on Medline from 1970 to 2005, and observed that the prevalence of HCV infection ranges from 0.4% in children, to 1.2% in healthy blood donors. Ali et al. (102) . Although between 75-85% of infections move on to chronic hepatitis C, the progress may be slow. Hence most people who are infected do not experience symptoms and are unaware of their infection. They are not able to benefit from available treatment that may clear them of the virus. They may also unknowingly spread the virus to others. Currently, there is no vaccine to prevent HCV infection. Effective but costly treatment is available. The high frequency and its contribution to premature mortality and disability call for massive awareness campaigns to combat the menace of this infectious disease.
Conclusions
The frequency of hepatitis C infection in Pakistan is high (4.7%), varying from 0.4% -33.7%, indicating pockets of infections. The frequency is significantly higher than in surrounding countries. The contribution of this high frequency to premature mortality and disability calls for massive awareness campaigns.
